124 related articles for article (PubMed ID: 37651878)
1. Discovery of N-(2-oxoethyl) sulfanilamide-derived inhibitors of KAT6A (MOZ) against leukemia by an isostere strategy.
Duan Y; Zhao Y; Li Z; Liu Z; Wang M; Wang X; Sun M; Song C; Yao Y
Eur J Med Chem; 2023 Nov; 260():115770. PubMed ID: 37651878
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Baell JB; Leaver DJ; Hermans SJ; Kelly GL; Brennan MS; Downer NL; Nguyen N; Wichmann J; McRae HM; Yang Y; Cleary B; Lagiakos HR; Mieruszynski S; Pacini G; Vanyai HK; Bergamasco MI; May RE; Davey BK; Morgan KJ; Sealey AJ; Wang B; Zamudio N; Wilcox S; Garnham AL; Sheikh BN; Aubrey BJ; Doggett K; Chung MC; de Silva M; Bentley J; Pilling P; Hattarki M; Dolezal O; Dennis ML; Falk H; Ren B; Charman SA; White KL; Rautela J; Newbold A; Hawkins ED; Johnstone RW; Huntington ND; Peat TS; Heath JK; Strasser A; Parker MW; Smyth GK; Street IP; Monahan BJ; Voss AK; Thomas T
Nature; 2018 Aug; 560(7717):253-257. PubMed ID: 30069049
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Benzoylsulfonohydrazides as Potent Inhibitors of the Histone Acetyltransferase KAT6A.
Leaver DJ; Cleary B; Nguyen N; Priebbenow DL; Lagiakos HR; Sanchez J; Xue L; Huang F; Sun Y; Mujumdar P; Mudududdla R; Varghese S; Teguh S; Charman SA; White KL; Katneni K; Cuellar M; Strasser JM; Dahlin JL; Walters MA; Street IP; Monahan BJ; Jarman KE; Sabroux HJ; Falk H; Chung MC; Hermans SJ; Parker MW; Thomas T; Baell JB
J Med Chem; 2019 Aug; 62(15):7146-7159. PubMed ID: 31256587
[TBL] [Abstract][Full Text] [Related]
4. The histone acetyltransferase KAT6A is recruited to unmethylated CpG islands via a DNA binding winged helix domain.
Weber LM; Jia Y; Stielow B; Gisselbrecht SS; Cao Y; Ren Y; Rohner I; King J; Rothman E; Fischer S; Simon C; Forné I; Nist A; Stiewe T; Bulyk ML; Wang Z; Liefke R
Nucleic Acids Res; 2023 Jan; 51(2):574-594. PubMed ID: 36537216
[TBL] [Abstract][Full Text] [Related]
5. The role of MOZ/KAT6A in hematological malignancies and advances in MOZ/KAT6A inhibitors.
Su J; Wang X; Bai Y; Sun M; Yao Y; Duan Y
Pharmacol Res; 2021 Dec; 174():105930. PubMed ID: 34626770
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Sharma S; Chung CY; Uryu S; Petrovic J; Cao J; Rickard A; Nady N; Greasley S; Johnson E; Brodsky O; Khan S; Wang H; Wang Z; Zhang Y; Tsaparikos K; Chen L; Mazurek A; Lapek J; Kung PP; Sutton S; Richardson PF; Greenwald EC; Yamazaki S; Jones R; Maegley KA; Bingham P; Lam H; Stupple AE; Kamal A; Chueh A; Cuzzupe A; Morrow BJ; Ren B; Carrasco-Pozo C; Tan CW; Bhuva DD; Allan E; Surgenor E; Vaillant F; Pehlivanoglu H; Falk H; Whittle JR; Newman J; Cursons J; Doherty JP; White KL; MacPherson L; Devlin M; Dennis ML; Hattarki MK; De Silva M; Camerino MA; Butler MS; Dolezal O; Pilling P; Foitzik R; Stupple PA; Lagiakos HR; Walker SR; Hediyeh-Zadeh S; Nuttall S; Spall SK; Charman SA; Connor T; Peat TS; Avery VM; Bozikis YE; Yang Y; Zhang M; Monahan BJ; Voss AK; Thomas T; Street IP; Dawson SJ; Dawson MA; Lindeman GJ; Davis MJ; Visvader JE; Paul TA
Cell Chem Biol; 2023 Oct; 30(10):1191-1210.e20. PubMed ID: 37557181
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents.
Priebbenow DL; Leaver DJ; Nguyen N; Cleary B; Lagiakos HR; Sanchez J; Xue L; Huang F; Sun Y; Mujumdar P; Mudududdla R; Varghese S; Teguh S; Charman SA; White KL; Shackleford DM; Katneni K; Cuellar M; Strasser JM; Dahlin JL; Walters MA; Street IP; Monahan BJ; Jarman KE; Jousset Sabroux H; Falk H; Chung MC; Hermans SJ; Downer NL; Parker MW; Voss AK; Thomas T; Baell JB
J Med Chem; 2020 May; 63(9):4655-4684. PubMed ID: 32118427
[TBL] [Abstract][Full Text] [Related]
8. The histone acetyltransferase KAT6B is required for hematopoietic stem cell development and function.
Bergamasco MI; Ranathunga N; Abeysekera W; Li-Wai-Suen CSN; Garnham AL; Willis SN; McRae HM; Yang Y; D'Amico A; Di Rago L; Wilcox S; Nutt SL; Alexander WS; Smyth GK; Voss AK; Thomas T
Stem Cell Reports; 2024 Apr; 19(4):469-485. PubMed ID: 38518784
[TBL] [Abstract][Full Text] [Related]
9. The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13).
Chinen Y; Taki T; Tsutsumi Y; Kobayashi S; Matsumoto Y; Sakamoto N; Kuroda J; Horiike S; Nishida K; Ohno H; Uike N; Taniwaki M
Genes Chromosomes Cancer; 2014 Apr; 53(4):299-308. PubMed ID: 24446090
[TBL] [Abstract][Full Text] [Related]
10. MOZ/KAT6A: a promising target for acute myeloid leukemia therapy.
Zhou C; Liu W; Duan Y
Future Med Chem; 2020 May; 12(9):759-761. PubMed ID: 32212924
[No Abstract] [Full Text] [Related]
11. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.
Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP
Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592
[TBL] [Abstract][Full Text] [Related]
12. MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.
Sheikh BN; Lee SC; El-Saafin F; Vanyai HK; Hu Y; Pang SH; Grabow S; Strasser A; Nutt SL; Alexander WS; Smyth GK; Voss AK; Thomas T
Blood; 2015 Mar; 125(12):1910-21. PubMed ID: 25605372
[TBL] [Abstract][Full Text] [Related]
13. MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway.
Sheikh BN; Phipson B; El-Saafin F; Vanyai HK; Downer NL; Bird MJ; Kueh AJ; May RE; Smyth GK; Voss AK; Thomas T
Oncogene; 2015 Nov; 34(47):5807-20. PubMed ID: 25772242
[TBL] [Abstract][Full Text] [Related]
14. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology.
Wiesel-Motiuk N; Assaraf YG
Drug Resist Updat; 2020 Dec; 53():100729. PubMed ID: 33130515
[TBL] [Abstract][Full Text] [Related]
15. MOZ increases p53 acetylation and premature senescence through its complex formation with PML.
Rokudai S; Laptenko O; Arnal SM; Taya Y; Kitabayashi I; Prives C
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3895-900. PubMed ID: 23431171
[TBL] [Abstract][Full Text] [Related]
16. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.
Yan F; Li J; Milosevic J; Petroni R; Liu S; Shi Z; Yuan S; Reynaga JM; Qi Y; Rico J; Yu S; Liu Y; Rokudai S; Palmisiano N; Meyer SE; Sung PJ; Wan L; Lan F; Garcia BA; Stanger BZ; Sykes DB; Blanco MA
Cancer Discov; 2022 Mar; 12(3):792-811. PubMed ID: 34853079
[TBL] [Abstract][Full Text] [Related]
17. Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression.
Zhao W; Mo H; Liu R; Chen T; Yang N; Liu Z
Br J Cancer; 2022 Jul; 127(2):202-210. PubMed ID: 35332266
[TBL] [Abstract][Full Text] [Related]
18. De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay.
Arboleda VA; Lee H; Dorrani N; Zadeh N; Willis M; Macmurdo CF; Manning MA; Kwan A; Hudgins L; Barthelemy F; Miceli MC; Quintero-Rivera F; Kantarci S; Strom SP; Deignan JL; ; Grody WW; Vilain E; Nelson SF
Am J Hum Genet; 2015 Mar; 96(3):498-506. PubMed ID: 25728775
[TBL] [Abstract][Full Text] [Related]
19. miR-143-3p represses leukemia cell proliferation by inhibiting KAT6A expression.
Xu D; Jiang J; He G; Zhou H; Ji C
Anticancer Drugs; 2022 Jan; 33(1):e662-e669. PubMed ID: 34459452
[TBL] [Abstract][Full Text] [Related]
20. HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer.
Jeselsohn R; Polyak K
Cell Chem Biol; 2023 Oct; 30(10):1183-1185. PubMed ID: 37863030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]